01308nam a2200193   4500001000700000010001500007100004100022101000800063200016700071210008300238215001700321330059500338606004100933606001600974606002200990606003301012606000901045710006001054384316  a929168063X  a20070531d1999       y0pory50      ba  aeng  aReport on the risk assessment of MBDB in the framework of the joint action on new synthetic drugsfEuropean Monitoring Centre for Drugs and Drug Addiction, EMCDDA  aLuxembourgcOffice for Official Publications of the European Communitiesd1999  a94 p.d21 cm  aForeword. Abbreviations. Introduction. Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs. Joint action concerning the information exchange, risk assessment and the control of new synthetic drugs. EMCDDA-EDU progress report on the joint action on new synthetic drugs. The pharmacotoxicology and neuropsychology of N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB). Sociological and criminological evidence on the risks of MBDB. Public health risks of MBDB: epidemiological evidence. References. Participants in the risk-assessment process.  aPREVENÇÃO DA TOXICODEPENDÊNCIA  aRELATÓRIO  aDROGA SINTÉTICA  aCOOPERAÇÃO INTERNACIONAL  aOEDT  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION